Two separate studies show some promising results for MS and a fat mass reduction in menopausal women with the use of melatonin supplementation. Firstly, there are some exciting implications for MS sufferers, reported in the September 2015 issue of Cell magazine. Researchers discovered a co-relation between higher wintertime levels of melatonin and a reduction in Multiple Sclerosis (MS) symptoms. Life Extension News published the findings. The actual research was conducted at Boston’s Brigham and Women’s Hospitals.
Dr. Quintana noted an improvement in 139 relapsing MS patients after treatment with a melatonin supplement in autumn and winter. During the study in both human and mouse models, melatonin was found to block the differentiation between pathogenic TH17 cells while it boosted the protective Tr1 cells.
“We found that melatonin has a protective effect,” said Dr. Quintana.He went on to say that “In the future melatonin or its derivatives may be used in MS patients after appropriate clinical trials are conducted and dosage is established. Dr. Quintana also said there is a seasonal variability in melatonin levels and that they control the balance between the ‘bad-guy’ pathogenic and the regulatory T cells. This is a welcome development in the treatment of MS and good news for those who suffer from the disease. Meanwhile, there are further great results from studies regarding the benefits of melatonin supplementation.
Life Extension News also reports that melatonin supplementation is associated with decreased fat mass in menopausal women. They said that from an article published on line on October 8, 2015, in Clinical Endocrinology, the outcome of a double-blind trial showed improvements in body composition in post menopausal women receiving melatonin. At the end of a study in which 81 women were given either 1 mg, 3 mg, or a placebo for an entire year, the women who received the melatonin were discovered to have a 6.9% reduction in fat mass and a 7.2% reduction in overall body fat percentage. This was a trial at Denmark ’s Aarhaus University and was initially carried out to see the effects of melatonin on women with osteopenia. One of the researchers, “Anne Kristina Amstrup stated, “To the best of our knowledge our study is the first human trial on lean tissue mass.” The researchers also note that melatonin is believed to direct human mesenchymal stem cells toward new bone cell formation at the same time inhibiting the formation of fat.
Exciting news from recent studies and can be the beginning of further therapeutic strategies against both osteoporosis and age-related changes in body composition.